Community of Metros

San Francisco SPCA Receives $100k Grant from The San Francisco Foundation to Support Keeping Families and Their Pets Together

Retrieved on: 
Tuesday, March 28, 2023
Partnership, 155th Street station (IND Concourse Line), Public health, Pet, San Francisco Foundation, Koret Foundation, Community of Metros, Animal, SAN, SFF, BIPOC, SPCA, San Francisco SPCA, San Francisco Bay Area, SF, Excelsior

SAN FRANCISCO, March 28, 2023 /PRNewswire/ -- Today, the San Francisco SPCA (SF SPCA) announced that it received a $100K grant from the San Francisco Foundation (SFF) to support its programs that keep families and their pets together. The grant will fund a variety of SF SPCA programs that address animal welfare as a social justice issue. San Francisco Foundation's investment comes as it celebrates its 75th anniversary of serving San Francisco Bay Area communities and the SF SPCA celebrates its 155th anniversary.

Key Points: 
  • SAN FRANCISCO, March 28, 2023 /PRNewswire/ -- Today, the San Francisco SPCA (SF SPCA) announced that it received a $100K grant from the San Francisco Foundation (SFF) to support its programs that keep families and their pets together.
  • The grant will fund a variety of SF SPCA programs that address animal welfare as a social justice issue.
  • San Francisco Foundation's investment comes as it celebrates its 75th anniversary of serving San Francisco Bay Area communities and the SF SPCA celebrates its 155th anniversary.
  • "For 75 years, the San Francisco Foundation, together with our donors and partners, has worked to create a Bay Area where everyone thrives," said Fred Blackwell, San Francisco Foundation CEO.

Nihon Kohden Introduces CoMET to Help Detect Early Warning of Patient Illness Through Artificial Intelligence

Retrieved on: 
Wednesday, January 18, 2023
Technology, Medical Devices, Hospitals, Health Technology, Cardiology, Practice Management, Biometrics, Biotechnology, Health, Artificial Intelligence, Continuous monitoring, Hospital, Vital signs, Disease, Intubation, Machine learning, Risk, Diagnosis, Advanced Medical Research Center, Patient, Sepsis, Artificial intelligence, Bleeding, Community of Metros, Acquisition, Cardiogenic shock, Medical device, Pharmaceutical industry, Nihon Kohden

Nihon Kohden acquired CoMET technology through its acquisition of AMP3D (Advanced Medical Predictive Devices, Diagnostics and Displays, Inc.) last year.

Key Points: 
  • Nihon Kohden acquired CoMET technology through its acquisition of AMP3D (Advanced Medical Predictive Devices, Diagnostics and Displays, Inc.) last year.
  • CoMET’s event trajectories provide clinicians with a visual tool for identifying potential patient deterioration, monitoring treatment efficacy, assessing patient acuity, and managing appropriate staffing ratios.
  • The Artificial Intelligence tool can also rank patients according to predicted risk of severe illness and display trajectories of deterioration and recovery.
  • Beyond the world’s first pulse oximeter, Nihon Kohden leverages its 70-year heritage to set the bar high, with industry-changing innovation for experts by experts.

VectivBio Announces Results of Extraordinary General Meeting

Retrieved on: 
Friday, December 9, 2022
Extraordinary general meeting, Acquisition, Respiration (physiology), MMA, Congenital disorders of amino acid metabolism, Manufacturing execution system, Degenerative disease, Short bowel syndrome, Propionic acidemia, NAMS, Community of Metros, Coenzyme A, University of Groningen, Growth, General partnership, Business administration, Pantetheine, University, Novartis, International business, Patient, SBS, Fine chemical

BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.

Key Points: 
  • BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.
  • Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio.
  • He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner.
  • His deep experience in life-science capital markets will benefit VectivBio as we enter our next stage of growth,” said Tom Woiwode, VectivBio Board Chairman.

VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, EST, MMA, Short bowel syndrome, Proxy, Propionic acidemia, SBS, Federal Council (Switzerland), Degenerative disease, Patient, Exercise, Respiration (physiology), Manufacturing execution system, Security (finance), Extraordinary general meeting, Congenital disorders of amino acid metabolism, CET, Community of Metros, Coronavirus, Pantetheine, Coenzyme A, Holding company, Pharmaceutical industry

The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.

Key Points: 
  • The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.
  • Shareholders shall be represented at the Extraordinary General Meeting exclusively by the independent proxy.
  • For information on how to exercise rights and issue voting instructions to the independent proxy, shareholders can access the invitation to the Extraordinary General Meeting at www.edocumentview.com/VECT.
  • These statements include, but are not limited to, statements concerning the timing of the Extraordinary General Meeting.

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Respiration (physiology), Coenzyme A, Propionic acidemia, SBS, Nasdaq, Congenital disorders of amino acid metabolism, Short bowel syndrome, MMA, Community of Metros, Manufacturing execution system, Conference, Patient, Degenerative disease, Pantetheine, Pharmaceutical industry

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022.

Key Points: 
  • BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022.
  • VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions.
  • VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs).
  • Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.

Raba Kistner Expanding Its Engineering Services in the Gulf Coast Region

Retrieved on: 
Thursday, November 10, 2022
Consulting, Engineering, Professional Services, Manufacturing, Engineering, Rio Grande Valley, Building material, Gulf, PE, Technology, Rio, Engineering News-Record, Community of Metros, Achievement, Landers, Ornelas, Observation, Growth, Venable, History, Wind, Management, Oil, Civil engineering, Gulf Coast of the United States

Engineering consulting and project management firm Raba Kistner announced its expansion in the Gulf Coast region.

Key Points: 
  • Engineering consulting and project management firm Raba Kistner announced its expansion in the Gulf Coast region.
  • Raba Kistner welcomes Ryan Venable, senior vice president and Gulf Coast marketplace leader to help establish the new offices and lead the firms growth strategy in the region, including Houston.
  • Bryan Landers has also joined Raba Kistner as senior project manager in the Beaumont office.
  • The expansion is part of a broader plan to accommodate growth, efficiently serve clients and leverage the companys expertise in the energy sector by providing geotechnical engineering consulting, construction materials engineering and testing (CoMET) services and environmental consulting services in the Gulf Coast region.

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on: 
Thursday, November 3, 2022
Patient, Pantetheine, Propionic acidemia, Compliance, Manufacturing execution system, Congenital disorders of amino acid metabolism, SBS, Respiration (physiology), Short bowel syndrome, GLOBE, FDA, Safety, PS, COVID-19, Nasdaq, Stoma, Study, Degenerative disease, STARS, Failure, U.S. Securities and Exchange Commission, Community of Metros, Forward-looking statement, Partnership, Drug development, Phrase, CIC, MMA, Security (finance), Coenzyme A, Medical imaging, Pharmaceutical industry

BASEL, Switzerland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s Phase 3 STARS (STudy of ApRglutide in SBS) pivotal study investigating the long-acting synthetic GLP-2 agonist apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF).

Key Points: 
  • This result is a testament to a successful operational effort based on our strong partnership with patients and investigators involved in this study.
  • STARS is a pivotal, global Phase 3 study enrolling approximately 144 patients with SBS-IF stratified 50/50 for CIC and stoma, with patients being evaluated over 48 weeks and 24 weeks respectively.
  • The study includes an improved PS weaning algorithm tailored to remnant bowel anatomy to enhance signal detection.
  • STARS is designed to establish a new standard of care for all patients with SBS-IF and to tailor apraglutide treatment to patients with distinct remnant bowel anatomy.

San Francisco SPCA Announces New Workforce Development Program, #ThanksToMaddie

Retrieved on: 
Thursday, October 27, 2022
Human, SCPA, Community of Metros, David Duffield, Safety, Bureau, YCD, Fund, Maddy Dychtwald, Program, Public health, Foundation, Culture, PETS, Dog, Industry, Veterinarian, Quality of life, Education, Veterinary medicine, CA, Bureau of Labor Statistics, GLOBE, SF, Cat, SPCA, Partnership, Medicine, Animal

Pleasanton, CA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The San Francisco Society for the Prevention of Cruelty to Animals (SF SCPA) is offering a three-month paid Community Medicine Education Training (CoMET) program.

Key Points: 
  • Pleasanton, CA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The San Francisco Society for the Prevention of Cruelty to Animals (SF SCPA) is offering a three-month paid Community Medicine Education Training (CoMET) program.
  • Thanks to Maddie, this support will help make veterinary medicine more accessible to those who have been traditionally underrepresented in the field.
  • Maddies Fund is proud of our long history of support for the San Francisco SPCA, said Mary Ippolitti-Smith, Executive Leadership Team, Maddies Fund.
  • The San Francisco SPCA is an independent, community-supported nonprofit animal welfare organization dedicated to saving, protecting, and providing immediate care for cats and dogs who are homeless, ill, or in need of an advocate.

VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

Retrieved on: 
Tuesday, October 18, 2022
808, U.S. Securities and Exchange Commission, MMA, Sale, Telephone, SEC filing, SEC, SBS, Short bowel syndrome, Coenzyme A, Nicollet Mall, LLC, Pantetheine, Jefferies Group, Risk, Patient, Manufacturing execution system, Madison Avenue, Degenerative disease, Attention, Nasdaq, Richard Driehaus, State Street, Community of Metros, Form, Propionic acidemia, Congenital disorders of amino acid metabolism, Phrase, GLOBE, Prospectus, Jefferies, Respiration (physiology), Forward-looking statement, Life insurance, Security (finance), Citadel

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.

Key Points: 
  • BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.
  • Before deducting the underwriting discounts and commissions and offering expenses, VectivBio received total gross proceeds of approximately $125 million.
  • Jefferies, SVB Securities and Piper Sandler acted as the joint book-running managers for the offering.
  • VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions.

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

Retrieved on: 
Thursday, October 13, 2022
808, U.S. Securities and Exchange Commission, MMA, Sale, Telephone, SEC filing, SEC, SBS, Short bowel syndrome, Coenzyme A, Nicollet Mall, LLC, Pantetheine, Jefferies Group, Risk, Patient, Manufacturing execution system, Madison Avenue, Degenerative disease, Attention, Nasdaq, Richard Driehaus, State Street, Community of Metros, Form, Propionic acidemia, Congenital disorders of amino acid metabolism, Phrase, GLOBE, Prospectus, Jefferies, Respiration (physiology), Forward-looking statement, Life insurance, Security (finance), Citadel

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.

Key Points: 
  • BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.
  • Before deducting the underwriting discounts and commissions and offering expenses, VectivBio expects to receive total gross proceeds of approximately $125 million.
  • The offering is expected to close on or about October 17, 2022, subject to satisfaction of customary closing conditions.
  • These statements include, but are not limited to, whether VectivBio will offer the ordinary shares or consummate the offering, and the timing, size and use of proceeds of the offering described herein.